TOPIGEN Pharmaceuticals to Present at the BIO 2008 International Convention



TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced that Lisa Nolan, Ph.D., Senior Vice President, Business Development, will make a corporate presentation at the BIO Business Forum as part of the 2008 BIO International Convention in San Diego, on June 19th at 11:45 AM PST in room 5A. Dr. Nolan, along with Mark Parry-Billings, Ph.D., Chief Development Officer, will also be available for one-on-one meetings during the conference. The company will be exhibiting at booth #4425, in the Canadian Quebec Pavilion. For more information, please visit http://www.bio2008.org/

    

About TOPIGEN

TOPIGEN is a privately held, clinical-stage company focused on developing new classes of inhaled drugs for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. TOPIGEN is actively progressing two drug candidates in Phase 2 trials, including TPI 1020, a novel anti-inflammatory for COPD and other respiratory disorders, and TPI ASM8, for severe and difficult-to-control asthma. These drug candidates target multiple pathways and pro-inflammatory mediators involved in chronic inflammatory pulmonary diseases.

Current venture investors include NovaQuest, MMV Financial, Inc., BDC Venture Capital, Fonds de solidarit FTQ, Desjardins Venture Capital, Caisse de Dpot et Placement du Qubec (Caisse), T2C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR. For more detailed information on TOPIGEN visit www.topigen.com.

IR/PR Contact:

Catherine Cloft

LaVoie Group

(978) 745-4200 X107





TOPIGEN Pharmaceuticals to Present at the BIO 2008 International Convention